Bluebird trumpets long-term data from beta-thalassaemia gene therapybluebird bio has presented long-term data from its Zynteglo one-time gene therapy for the blood disorder beta-thalassaemia, as Share XBluebird trumpets long-term data from beta-thalassaemia gene therapyhttps://pharmaphorum.com/news/bluebird-trumpets-long-term-data-from-beta-thalassaemia-gene-therapy/
ASH: CRISPR, Vertex’ CTX001 hits the mark in red cell disordersA gene-editing drug developed by CRISPR Therapeutics and Vertex Pharma has achieved “remarkable” improvements in patients with beta Share XASH: CRISPR, Vertex’ CTX001 hits the mark in red cell disordershttps://pharmaphorum.com/news/ash-crispr-vertex-ctx001-hits-the-mark-in-red-cell-disorders/
CHMP backs BMS’ first-in-class anaemia drug ReblozylBristol-Myers Squibb has moved a step closer to EMA approval of Reblozyl, a therapy for anaemia that has Share XCHMP backs BMS’ first-in-class anaemia drug Reblozylhttps://pharmaphorum.com/news/chmp-backs-bms-first-in-class-anaemia-drug-reblozyl/
CRISPR trials yield encouraging data in blood disordersData on the first two patients to be treated with a CRISPR-based drug for the blood disorders beta Share XCRISPR trials yield encouraging data in blood disordershttps://pharmaphorum.com/news/crispr-trials-yield-encouraging-data-in-blood-disorders/
Celgene scores FDA okay for thalassaemia drug ReblozylThe FDA has approved Celgene and Acceleron’s Reblozyl, which is the first drug to be approved in the Share XCelgene scores FDA okay for thalassaemia drug Reblozylhttps://pharmaphorum.com/news/celgene-scores-fda-okay-for-thalassaemia-drug-reblozyl/
bluebird claims first approval for gene therapy Zynteglo in EUbluebird bio has its first ever product approval, getting a green light from the EMA for Zynteglo, its Share Xbluebird claims first approval for gene therapy Zynteglo in EUhttps://pharmaphorum.com/news/bluebird-claims-first-approval-for-gene-therapy-zynteglo-in-eu/
